Share:
DEDHAM, Mass., April 15, 2021 /PRNewswire/ Atlantic Power Corporation (NYSE:AT) (TSX:ATP) ( Atlantic Power or the Company ) announced today that the parties to the previously announced proposed transaction among Atlantic Power, Atlantic Power Preferred Equity Ltd. ( APPEL ), Atlantic Power Limited Partnership ( APLP ) and certain affiliates (collectively the Purchasers ) of infrastructure funds managed by I Squared Capital Advisors (US) LLC (the Transaction ) are continuing to work through the steps required to close the Transaction without the approval of holders of the Company s 6.00% Series E convertible unsecured subordinated debentures due January 31, 2025 (the Convertible Debentures ).
It is expected that these steps will still offer to the holders of Convertible Debentures the benefit of the make whole premium contemplated by the indenture governing the Convertible Debentures. Additional details will be provided once these steps are substantially finalized
Atlantic Power Provides an Update on Convertible Debentureholder Meeting
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Aegion Enters into Amended Merger Agreement with Affiliates of New Mountain Capital to Increase Consideration to $30 00 Per Share in Cash
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Rigel Announces Closing of Strategic Collaboration with Lilly
News provided by
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., April 7, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. Rigel and Lilly entered a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Pursuant to the collaboration, Lilly will also lead all clinical development of penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.
Atlantic Power Announces Common and Preferred Shareholder Approval of I Squared Transaction
News provided by
Share this article
Share this article
DEDHAM, Mass., April 7, 2021 /PRNewswire/ Atlantic Power Corporation (NYSE: AT) (TSX: ATP) ( Atlantic Power or the Company ) announced that, at today s special meetings of common shareholders ( Common Shareholders ) of Atlantic Power and preferred shareholders ( Preferred Shareholders ) of Atlantic Power Preferred Equity Ltd. ( APPEL ), shareholders voted to approve the previously announced proposed transaction among Atlantic Power, APPEL, Atlantic Power Limited Partnership and certain affiliates (collectively the Purchasers ) of infrastructure funds managed by I Squared Capital Advisors (US) LLC (the Transaction ). Upon closing of the Transaction, all of the common shares of Atlantic Power ( Common Shares ) will be acquired for US$3.03 in cash per Common Share (less applicable withholdings) and all of the preferred shares of